Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Filson

Showing results (111-120 of 121) with videos related to

Pageof 13
Sort By:
The Journal of Urology|October 26, 2019
African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance StudyJeannette M Schenk, Lisa F Newcomb, Yingye Zheng, et al.
The Journal of Urology|January 18, 2020
Reply by AuthorsJeannette M Schenk, Lisa F Newcomb, Yingye Zheng, et al.
The Journal of Urology|April 30, 2025
Magnetic Resonance Imaging at Second Surveillance Biopsy After Diagnosis in Patients With Grade Group 1 Prostate Cancer in the Canary Prostate Active Surveillance StudyMeera R Chappidi, Lisa F Newcomb, Yingye Zheng, et al.
Cancer|September 13, 2021
Treatment in the absence of disease reclassification among men on active surveillance for prostate cancerPeter S Kirk, Kehao Zhu, Yingye Zheng, et al.
The Journal of Urology|July 13, 2022
Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active SurveillanceChristopher P Filson, Kehao Zhu, Yijian Huang, et al.
Cancer Medicine|April 25, 2022
Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillanceLauren Brady, Lisa F Newcomb, Kehao Zhu, et al.
JAMA|May 30, 2024
Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate CancerLisa F Newcomb, Jeannette M Schenk, Yingye Zheng, et al.
Histopathology|June 3, 2024
Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stageJane K Nguyen, Lara R Harik, Eric A Klein, et al.
Nature|December 13, 2019
An intra-tumoral niche maintains and differentiates stem-like CD8 T cellsCaroline S Jansen, Nataliya Prokhnevska, Viraj A Master, et al.
Research Square|August 16, 2024
Neoadjuvant cabozantinib restores CD8+ T cells in patients with locally advanced non-metastatic clear cell renal cell carcinoma: a phase 2 trialMehmet A Bilen, BaoHan T Vo, Yuan Liu, et al.
Pageof 13

Showing results (111-120 of 121) with videos related to

Sort By:
Pageof 13
The Journal of Urology|October 26, 2019
African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance StudyJeannette M Schenk, Lisa F Newcomb, Yingye Zheng, et al.
The Journal of Urology|January 18, 2020
Reply by AuthorsJeannette M Schenk, Lisa F Newcomb, Yingye Zheng, et al.
The Journal of Urology|April 30, 2025
Magnetic Resonance Imaging at Second Surveillance Biopsy After Diagnosis in Patients With Grade Group 1 Prostate Cancer in the Canary Prostate Active Surveillance StudyMeera R Chappidi, Lisa F Newcomb, Yingye Zheng, et al.
Cancer|September 13, 2021
Treatment in the absence of disease reclassification among men on active surveillance for prostate cancerPeter S Kirk, Kehao Zhu, Yingye Zheng, et al.
The Journal of Urology|July 13, 2022
Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active SurveillanceChristopher P Filson, Kehao Zhu, Yijian Huang, et al.
Cancer Medicine|April 25, 2022
Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillanceLauren Brady, Lisa F Newcomb, Kehao Zhu, et al.
JAMA|May 30, 2024
Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate CancerLisa F Newcomb, Jeannette M Schenk, Yingye Zheng, et al.
Histopathology|June 3, 2024
Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stageJane K Nguyen, Lara R Harik, Eric A Klein, et al.
Nature|December 13, 2019
An intra-tumoral niche maintains and differentiates stem-like CD8 T cellsCaroline S Jansen, Nataliya Prokhnevska, Viraj A Master, et al.
Research Square|August 16, 2024
Neoadjuvant cabozantinib restores CD8+ T cells in patients with locally advanced non-metastatic clear cell renal cell carcinoma: a phase 2 trialMehmet A Bilen, BaoHan T Vo, Yuan Liu, et al.
Pageof 13